EUCTR2010-019638-28-LT进行中（未招募）不适用
INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS – A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY - ADVANCE
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,166
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age = 18 years.
- •2. End stage kidney disease and a suitable candidate for primary renal transplantation or retransplantation (unless the graft was lost from rejection within one year).
- •3. Receiving a kidney transplant from a deceased or living (non HLA identical) donor with compatible AB0 blood type.
- •4. Female subjects of childbearing potential must have a negative serum or urine pregnancy test at enrollment and must agree to maintain highly effective birth control during the study.
- •A highly effective method of birth control is defined as those which result in a low failure rate (CPMP/ICH/286/95 modified) of less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomized partner.
- •5. Capable of understanding the purpose and risks of the study, fully informed and having given written informed consent (signed Informed Consent has been obtained).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 875
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 290
排除标准
- •1. Receiving or having previously received an organ transplant other than a kidney.
- •2. Cold ischemia time of the donor kidney > 30 hours.
- •3. Panel Reactive Antibody (PRA) >20%. (Highest level in 6 months prior to transplant.)
- •4. Previous renal transplant lost within one year for immunological reasons.
- •5. Receiving a graft from a non-heart-beating donor other than of Maastricht category 3 (withdrawal of support awaiting cardiac arrest).
- •6. Significant liver disease, defined as having continuously elevated SGPT/ALT and/or
- •SGOT/AST and/or total bilirubin levels = 2 times the upper value of the normal range of the investigational site or is receiving a graft from a hepatitis C or B positive donor.
- •7. Diagnosis of Diabetes Mellitus prior to transplantation (treated with prescribed
- •medications or diet controlled) or where there is evidence of a previous positive OGTT in the patient's medical history or previous diagnosis of gestational diabetes or pre-Baseline HbA1C =6.5%.
- •8. Requiring initial sequential or parallel therapy with immunosuppressive antibody
- •preparation(s).
- •9. Requiring ongoing dosing with a systemic immunosuppressive drug prior to
- •transplantation (e.g. for Lupus Disease, FSGN etc) other than minimal levels of
- •immunosuppressant following failure of a previous transplantation without nephrectomy.
- •10. Where Physician considers long term steroid treatment is necessary for the prevention of recurrent auto immune mediated renal disease or if the subject requires ongoing dosing with corticosteroids during the study for any other condition.
- •11. Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer.
- •12. Pregnant woman or breast-feeding mother.
- •13. Subject or donor known to be HIV positive.
- •14. Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids,
- •Basiliximab, mycophenolate mofetil or any of the product excipients.
- •15. Evidence of malignant disease within the last 5 years other than Basal Cell Carcinoma or Squamous Cell Carcinoma.
- •16. Currently participating in another clinical trial and/or has taken an investigational drug within 28 days prior to randomization.
- •17. Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator.
- •18. Unlikely to comply with the visits scheduled in the protocol.
研究者
相似试验
进行中（未招募）
不适用
Studying the onset of Diabetes Mellitus in patients with a kidney tranplant getting anti-rejection therapy with Advagraf when used with or without steroids.Prophylaxis of rejection in kidney allograft recipients (by immunosuppression)MedDRA version: 14.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-019638-28-HUAstellas Pharma Europe Ltd.1,166
进行中（未招募）
不适用
Studying the onset of Diabetes Mellitus in patients with a kidney tranplant getting anti-rejection therapy with Advagraf when used with or without steroids.EUCTR2010-019638-28-EEAstellas Pharma Europe Ltd.1,166
进行中（未招募）
1 期
INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS – A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY - ADVANCEEUCTR2010-019638-28-SKAstellas Pharma Europe Ltd.1,166
进行中（未招募）
不适用
Studying the onset of Diabetes Mellitus in patients with a kidney tranplant getting anti-rejection therapy with Advagraf when used with or without steroids.EUCTR2010-019638-28-CZAstellas Pharma Europe Ltd.1,166
进行中（未招募）
不适用
INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS – A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY - ADVANCEProphylaxis of rejection in kidney allograft recipients (by immunosuppression)MedDRA version: 13.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-019638-28-FIAstellas Pharma Europe Ltd.1,166